July 25, 2016 3:49 AM ET


Company Overview of PhaseBio Pharmaceuticals, Inc.

Company Overview

PhaseBio Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs that focus on endocrine and metabolic disorders, and cardiovascular diseases. Its development candidates include PE0139, a novel super-long-acting basal insulin-ELP fusion for weekly dosing; and PB1046, a weekly VIP receptor agonist for treatment of acute and chronic heart failure and Duchenne muscular dystrophy-associated cardiomyopathy. PhaseBio Pharmaceuticals, Inc. was formerly known as Phase Bioscience, Inc. and changed its name to PhaseBio Pharmaceuticals, Inc. in November 2008. The company was founded in 2002 and is based in Malvern, Pennsylvania.

One Great Valley Parkway

Suite 30

Malvern, PA 19355

United States

Founded in 2002





Key Executives for PhaseBio Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 51
Executive Chairman
Age: 47
Co-Founder and Director
Chief Financial Officer
Age: 51
Senior Vice President of Clinical Development
Compensation as of Fiscal Year 2016.

PhaseBio Pharmaceuticals, Inc. Key Developments

PhaseBio Pharmaceuticals, Inc. Appoints John S. Lee as Chief Medical Officer and John P. Sharp as Chief Financial Officer

PhaseBio Pharmaceuticals, Inc. announced the expansion of its leadership teams in Malvern, PA, and San Diego, CA, effective April 18, 2016. John S. Lee, M.D., Ph.D., has been appointed as Chief Medical Officer and will be based at PhaseBio’s corporate headquarters in Malvern. John P. Sharp, CPA, has been named as Chief Financial Officer and will be based in San Diego. Dr. Lee joins PhaseBio from Quintiles, where he served as Vice President & Global Head, Cardiovascular Center of Excellence. Mr. Sharp joins PhaseBio from HUYA Bioscience International, where he served as Chief Financial Officer.

PhaseBio Pharmaceuticals Inc. Gives the Exclusive Rights to its Drug-Delivery Technology for Use in Treating Cancer to Duke University

PhaseBio Pharmaceuticals Inc. has entered into a deal giving the exclusive rights to its drug-delivery technology for use in treating cancer to Duke University. PhaseBio has retained development and commercialization rights to all other applications of its elastin-like polypetide [ELP] technology platform.

PhaseBio Pharmaceuticals, Inc. Presents at 15th Annual Needham Healthcare Conference, Apr-13-2016 03:00 PM

PhaseBio Pharmaceuticals, Inc. Presents at 15th Annual Needham Healthcare Conference, Apr-13-2016 03:00 PM. Venue: The Westin NY Grand Central Hotel, 212 East 42nd Street, New York, NY 10017, United States. Speakers: Jonathan P. Mow, Chief Executive Officer and Director.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact PhaseBio Pharmaceuticals, Inc., please visit www.phasebio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.